|
MYLIP |
myosin regulatory light chain interacting protein |
- VLDLR internalisation and degradation
- NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
|
NCOA1 |
nuclear receptor coactivator 1 |
- RORA activates gene expression
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- Recycling of bile acids and salts
- Synthesis of bile acids and bile salts
- Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol
- Synthesis of bile acids and bile salts via 27-hydroxycholesterol
- PPARA activates gene expression
- PPARA activates gene expression
- Endogenous sterols
- Transcriptional activation of mitochondrial biogenesis
- Activation of gene expression by SREBF (SREBP)
- HATs acetylate histones
- Transcriptional regulation of white adipocyte differentiation
- Transcriptional regulation of white adipocyte differentiation
- SUMOylation of transcription cofactors
- Regulation of lipid metabolism by PPARalpha
- Circadian Clock
- Estrogen-dependent gene expression
- NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
- NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis
|
- Genistein
- Corticosterone
- Prinaberel
- ERB-196
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE
- 2-(5-HYDROXY-NAPHTHALEN-1-YL)-1,3-BENZOOXAZOL-6-OL
- TO-901317
- 1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL
- 4-(4-HYDROXYPHENYL)-1-NAPHTHALDEHYDE OXIME
- 5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-CARBONITRILE
- GW-590735
- 3-BROMO-6-HYDROXY-2-(4-HYDROXYPHENYL)-1H-INDEN-1-ONE
- 3-(6-HYDROXY-NAPHTHALEN-2-YL)-BENZO[D]ISOOXAZOL-6-OL
- (1R,3R)-5-[(2E)-3-{(1S,3R)-2,2,3-trimethyl-3-[6,6,6-trifluoro-5-hydroxy-5-(trifluoromethyl)hex-3-yn-1-yl]cyclopentyl}prop-2-en-1-ylidene]cyclohexane-1,3-diol
- 3,20-Pregnanedione
- Indeglitazar
- (8alpha,10alpha,13alpha,17beta)-17-[(4-hydroxyphenyl)carbonyl]androsta-3,5-diene-3-carboxylic acid
- Myristic acid
- 1,3-CYCLOHEXANEDIOL, 4-METHYLENE-5-[(2E)-[(1S,3AS,7AS)-OCTAHYDRO-1-(5-HYDROXY-5-METHYL-1,3-HEXADIYNYL)-7A-METHYL-4H-INDEN-4-YLIDENE]ETHYLIDENE]-, (1R,3S,5Z)
- Aleglitazar
|
|
|
NCOA2 |
nuclear receptor coactivator 2 |
- RORA activates gene expression
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- Recycling of bile acids and salts
- Synthesis of bile acids and bile salts
- Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol
- Synthesis of bile acids and bile salts via 27-hydroxycholesterol
- PPARA activates gene expression
- PPARA activates gene expression
- Endogenous sterols
- Transcriptional activation of mitochondrial biogenesis
- Activation of gene expression by SREBF (SREBP)
- HATs acetylate histones
- Transcriptional regulation of white adipocyte differentiation
- Transcriptional regulation of white adipocyte differentiation
- SUMOylation of transcription cofactors
- Regulation of lipid metabolism by PPARalpha
- Circadian Clock
- Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
- Estrogen-dependent gene expression
|
- Diethylstilbestrol
- Genistein
- Metribolone
- 17-METHYL-17-ALPHA-DIHYDROEQUILENIN
- 4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol
- TO-901317
- 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
- (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL
- 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
- 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
- 2-chloro-5-nitro-N-phenylbenzamide
- dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate
- 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol
- 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL
- (2E,4E)-11-METHOXY-3,7,11-TRIMETHYLDODECA-2,4-DIENOIC ACID
- DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE
- 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- Tributyltin
- 2-(4-hydroxyphenyl)benzo[b]thiophen-6-ol
- Estradiol acetate
- Estradiol benzoate
- Estradiol cypionate
- Estradiol dienanthate
- Estradiol valerate
|
|
|
NCOA3 |
nuclear receptor coactivator 3 |
- PPARA activates gene expression
- Transcriptional regulation of white adipocyte differentiation
- Transcriptional regulation of white adipocyte differentiation
- Activation of anterior HOX genes in hindbrain development during early embryogenesis
- MAPK6/MAPK4 signaling
- Estrogen-dependent gene expression
|
|
|
|
NCOA4 |
nuclear receptor coactivator 4 |
|
|
|
|
NCOA6 |
nuclear receptor coactivator 6 |
- RORA activates gene expression
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- PPARA activates gene expression
- PPARA activates gene expression
- Transcriptional activation of mitochondrial biogenesis
- Activation of gene expression by SREBF (SREBP)
- Transcriptional regulation of white adipocyte differentiation
- Regulation of lipid metabolism by PPARalpha
- Circadian Clock
- Activation of anterior HOX genes in hindbrain development during early embryogenesis
|
|
|
|
NCOR1 |
nuclear receptor corepressor 1 |
- Nuclear signaling by ERBB4
- Nuclear signaling by ERBB4
- NR1D1 (REV-ERBA) represses gene expression
- PPARA activates gene expression
- PPARA activates gene expression
- NOTCH1 Intracellular Domain Regulates Transcription
- Transcriptional activation of mitochondrial biogenesis
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- HDACs deacetylate histones
- Notch-HLH transcription pathway
- Transcriptional regulation of white adipocyte differentiation
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by PPARalpha
- Circadian Clock
- Circadian Clock
- Activation of anterior HOX genes in hindbrain development during early embryogenesis
- Loss of MECP2 binding ability to the NCoR/SMRT complex
- Regulation of MECP2 expression and activity
- NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
- HCMV Early Events
- NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis
|
|
|
|
NCOR2 |
nuclear receptor corepressor 2 |
- PPARA activates gene expression
- NOTCH1 Intracellular Domain Regulates Transcription
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- HDACs deacetylate histones
- Notch-HLH transcription pathway
- Transcriptional regulation of white adipocyte differentiation
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- SUMOylation of transcription cofactors
- Regulation of lipid metabolism by PPARalpha
- Loss of MECP2 binding ability to the NCoR/SMRT complex
- Regulation of MECP2 expression and activity
- NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
- HCMV Early Events
- NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis
|
|
|
|
NDE1 |
nudE neurodevelopment protein 1 |
- Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
- Separation of Sister Chromatids
- Resolution of Sister Chromatid Cohesion
- Regulation of PLK1 Activity at G2/M Transition
- Loss of Nlp from mitotic centrosomes
- Recruitment of mitotic centrosome proteins and complexes
- Loss of proteins required for interphase microtubule organization from the centrosome
- Recruitment of NuMA to mitotic centrosomes
- Anchoring of the basal body to the plasma membrane
- RHO GTPases Activate Formins
- Mitotic Prometaphase
- AURKA Activation by TPX2
- EML4 and NUDC in mitotic spindle formation
|
|
|
|
NELFCD |
negative elongation factor complex member C/D |
- Formation of RNA Pol II elongation complex
- Formation of the Early Elongation Complex
- Formation of HIV elongation complex in the absence of HIV Tat
- Formation of the HIV-1 Early Elongation Complex
- Formation of HIV-1 elongation complex containing HIV-1 Tat
- Formation of HIV-1 elongation complex containing HIV-1 Tat
- Pausing and recovery of Tat-mediated HIV elongation
- Abortive elongation of HIV-1 transcript in the absence of Tat
- Tat-mediated HIV elongation arrest and recovery
- Tat-mediated elongation of the HIV-1 transcript
- HIV elongation arrest and recovery
- Pausing and recovery of HIV elongation
- RNA Polymerase II Pre-transcription Events
- TP53 Regulates Transcription of DNA Repair Genes
- RNA Polymerase II Transcription Elongation
|
|
|
|
NFKB1 |
nuclear factor kappa B subunit 1 |
- Activation of NF-kappaB in B cells
- RIP-mediated NFkB activation via ZBP1
- Regulated proteolysis of p75NTR
- Downstream TCR signaling
- NF-kB is activated and signals survival
- Senescence-Associated Secretory Phenotype (SASP)
- FCERI mediated NF-kB activation
- DEx/H-box helicases activate type I IFN and inflammatory cytokines production
- PKMTs methylate histone lysines
- Transcriptional regulation of white adipocyte differentiation
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- Interleukin-1 processing
- IkBA variant leads to EDA-ID
- CLEC7A (Dectin-1) signaling
- CD209 (DC-SIGN) signaling
- CLEC7A/inflammasome pathway
- MAP3K8 (TPL2)-dependent MAPK1/3 activation
- Neutrophil degranulation
- The NLRP3 inflammasome
- Transcriptional Regulation by VENTX
- Interleukin-1 signaling
- TRAF6 mediated NF-kB activation
- HCMV Early Events
- Purinergic signaling in leishmaniasis infection
|
- Donepezil
- Pseudoephedrine
- Thalidomide
- Pranlukast
- HE3286
- P54
- NOX-700
- SGN-30
- Custirsen
- NF-kappaB Decoy
- Andrographolide
- Triflusal
- Glycyrrhizic acid
- Fish oil
- SC-236
|
|
|
NISCH |
nischarin |
|
- Tizanidine
- Agmatine
- Moxonidine
|
|
|
NLRP10 |
NLR family pyrin domain containing 10 |
|
|
|
|
NONO |
non-POU domain containing octamer binding |
|
|
|
|
NR0B1 |
nuclear receptor subfamily 0 group B member 1 |
|
- Dexamethasone
- Dexamethasone acetate
|
- Glycerol kinase deficiency (GKD), including: Hyperglycerolemia; Chromosome Xp21 deletion syndrome; Adrenal hypoplasia, congenital (AHC); Duchenne muscular dystrophy (DMD)
- 46,XY disorders of sex development (Disorders of gonadal development), including: Gonadal agenesis; Complete and partial gonadal dysgenesis; Testis regression; Ovotesticular DSD
|
|
NR0B2 |
nuclear receptor subfamily 0 group B member 2 |
- Nuclear Receptor transcription pathway
|
|
|
|
NR2C1 |
nuclear receptor subfamily 2 group C member 1 |
- Nuclear Receptor transcription pathway
- SUMOylation of intracellular receptors
|
|
|
|
NR2C2 |
nuclear receptor subfamily 2 group C member 2 |
- Nuclear Receptor transcription pathway
|
|
|
|
NR3C1 |
nuclear receptor subfamily 3 group C member 1 |
- HSP90 chaperone cycle for steroid hormone receptors (SHR)
- Circadian Clock
- SUMOylation of intracellular receptors
- PTK6 Expression
- Regulation of RUNX2 expression and activity
- FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
- Potential therapeutics for SARS
|
- Flunisolide
- Diflorasone
- Alclometasone
- Medrysone
- Amcinonide
- Fluorometholone
- Megestrol acetate
- Levonorgestrel
- Beclomethasone dipropionate
- Progesterone
- Spironolactone
- Betamethasone
- Desoximetasone
- Fluticasone propionate
- Fluocinolone acetonide
- Ulobetasol
- Triamcinolone
- Prednisone
- Flumethasone
- Fludrocortisone
- Norethisterone
- Hydrocortisone
- Mometasone
- Hydrocortamate
- Mifepristone
- Clocortolone
- Flurandrenolide
- Prednisolone
- Loteprednol etabonate
- Rimexolone
- Methylprednisolone
- Clobetasol propionate
- Fluocinonide
- Prednicarbate
- Fluoxymesterone
- Budesonide
- Dexamethasone
- Desonide
- Cortisone acetate
- Paramethasone
- Drospirenone
- Ciclesonide
- Hexane-1,6-Diol
- Aldosterone
- ORG-34517
- Difluprednate
- Ulipristal
- Fluticasone furoate
- Tixocortol
- Difluocortolone
- Gestrinone
- Deflazacort
- Onapristone
- Cortivazol
- Clobetasone
- Fluticasone
- Mometasone furoate
- Hydrocortisone aceponate
- Hydrocortisone acetate
- Hydrocortisone butyrate
- Hydrocortisone cypionate
- Hydrocortisone phosphate
- Hydrocortisone probutate
- Hydrocortisone valerate
- Segesterone acetate
- Prednisolone phosphate
- Dexamethasone acetate
- Betamethasone phosphate
- Prednisolone acetate
|
- 46,XX disorders of sex development (Disorders related to androgen excess), including: Congenital adrenal hyperplasias; Glucocorticoid resistance; Aromatase deficiency
|
|
NR3C2 |
nuclear receptor subfamily 3 group C member 2 |
- HSP90 chaperone cycle for steroid hormone receptors (SHR)
- SUMOylation of intracellular receptors
|
- Nimodipine
- Progesterone
- Spironolactone
- Fluticasone propionate
- Testosterone
- Fludrocortisone
- Eplerenone
- Clobetasol propionate
- Felodipine
- Desoxycorticosterone pivalate
- Drospirenone
- Stanolone
- Metribolone
- Aldosterone
- Corticosterone
- Desoxycorticosterone acetate
- Fluticasone furoate
- Fluticasone
- Testosterone cypionate
- Testosterone enanthate
- Testosterone undecanoate
- Stanolone acetate
|
- Hyperkalemic distal renal tubular acidosis (RTA type 4), including the following two diseases: Pseudohypoaldosteronism type I (PHA1); Pseudohypoaldosteronism type II (Gordon's syndrome)
- Hypertension exacerbated in pregnancy
|